Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ASH18

- PMLiVE

Amgen shares new Otezla data at American Academy of Dermatology congress 2022

Around 125 million people worldwide have psoriasis, including an estimated 14 million people in Europe

- PMLiVE

Sanofi reveals $330m collaboration with Blackstone Life Sciences

The partnership will focus on innovative treatment for multiple myeloma

- PMLiVE

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

Lung cancer is recorded as being the third most common cancer, with an estimated 48,000 new cases diagnosed in the UK every year

White paper: Are we prepared for the influx of CAR-Ts?

Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies

Research Partnership

- PMLiVE

Janssen and Legend Biotech’s Carvykti receives FDA approval for patients with relapsed or refractory multiple myeloma

In the study, 98% of patients with relapsed or refractory multiple myeloma responded to a one-off treatment of the drug

- PMLiVE

Amgen’s Lumakras shows promising results for patients with advanced pancreatic cancer

The results from the phase 1/2 trial showed encouraging and clinically meaningful anticancer activity in patients with the KRAS G12C-mutation

- PMLiVE

Improving outcomes in oncology: patient centricity and mental health

A key challenge in healthcare is how to proactively address unmet needs using patient-centric campaigns and resources, particularly in a time when ‘in-person’ care is limited. How can this be...

Mednet Group

- PMLiVE

World Cancer Day – February 2022

World Cancer Day is celebrated around the world in February in February and innovative Trials wants to take this opportunity to raise awareness around cancer

Innovative Trials

- PMLiVE

No green light from NICE for innovative cancer treatments

The Institute of Cancer Research is asking for more flexibility and consideration to make it easier for cancer patients to access new treatments on the NHS

- PMLiVE

Amgen and Plexium announce new research collaboration worth over $500m

The two companies will work to identify and develop new treatments for cancer and other serious diseases

- PMLiVE

BMS and Century Therapeutics agree on deal potentially worth over $3bn

The collaboration unites Century’s iPSC-derived allogeneic cell therapy line with BMS’s record in developing oncology drugs and cell therapies

- PMLiVE

Amgen’s Lumykras receives conditional marketing authorisation from EC

The drug is the first targeted therapy for patients diagnosed with advanced NSCLC with the KRAS G12C mutation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links